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OBJECTIVE—Cerebral edema (CE) is a potentially life-threat-
ening complication of diabetic ketoacidosis (DKA) in children.
Osmotic ﬂuctuations during DKA treatment have been consid-
ered responsible, but recent data instead suggest that cerebral
hypoperfusion may be involved and that activation of cerebral
ion transporters may occur. Diminished cerebral blood ﬂow
(CBF) during DKA, however, has not been previously demon-
strated. We investigated CBF and edema formation in a rat model
of DKA and determined the effects of bumetanide, an inhibitor of
Na-K-Cl cotransport.
RESEARCH DESIGN AND METHODS—Juvenile rats with
streptozotocin-induced DKA were treated with intravenous sa-
line and insulin, similar to human treatment protocols. CBF was
determined by magnetic resonance (MR) perfusion–weighted
imaging before and during treatment, and CE was assessed by
determining apparent diffusion coefﬁcients (ADCs) using MR
diffusion–weighted imaging.
RESULTS—CBF was signiﬁcantly reduced in DKA and was
responsive to alterations in pCO2. ADC values were reduced,
consistent with cell swelling. The reduction in ADCs correlated
with dehydration, as reﬂected in blood urea nitrogen concentra-
tions. Bumetanide caused a rapid rise in ADCs of DKA rats
without signiﬁcantly changing CBF, while saline/insulin caused a
rapid rise in CBF and a gradual rise in ADCs. DKA rats treated
with bumetanide plus saline/insulin showed a trend toward more
rapid rise in cortical ADCs and a larger rise in striatal CBF than
those observed with saline/insulin alone.
CONCLUSIONS—These data demonstrate that CE in DKA is
accompanied by cerebral hypoperfusion before treatment and
suggest that blocking Na-K-Cl cotransport may reduce cerebral
cell swelling. Diabetes 57:2588–2594, 2008
D
iabetic ketoacidosis (DKA) occurs frequently in
children with type 1 diabetes. A total of 25–40
percent of children with new-onset type 1 dia-
betes present with DKA, and DKA can occur in
children with known diabetes during episodes of illness,
poor compliance, or malfunction of diabetes care equip-
ment such as insulin pumps (1,2). Cerebral edema (CE) is
the most feared complication of DKA in children (3–5). CE
has a high mortality rate (21–24%), and survivors often
have permanent neurological deﬁcits (15–35%) (5,6). CE is
the major diabetes-related cause of mortality in children
with type 1 diabetes and is responsible for 50–85% of
diabetes-related deaths (7–9).
Asymptomatic CE is thought to occur with much greater
frequency than clinically apparent CE and may be present
in the majority of DKA episodes in children (10–12).
Studies utilizing sequential computed tomography or mag-
netic resonance (MR) scanning in children with DKA
without signiﬁcant neurological abnormalities have shown
evidence of CE at presentation (10), demonstrated by
decreased size of the cerebral ventricles, and that this
edema likely worsens during therapy (10–12). Thus, the
development of symptomatic CE in 1% of children with
DKA may represent the most severe presentation of a
more common pathophysiological phenomenon.
Osmotic ﬂuctuations during DKA treatment have been
presumed to play a central role in causing CE, but prelim-
inary work by our group suggests instead that DKA-related
CE may be mechanistically similar to that which occurs in
the setting of strokes or other ischemic brain injury. Rats
with DKA manifest a reduction of apparent diffusion
coefﬁcient (ADC) values for brain water, indicating cyto-
toxic edema, and administration of the Na-K-Cl cotrans-
port inhibitor bumetanide, which has been shown to
reduce both astrocyte and brain microvascular endothelial
cell swelling under hypoxic and ischemic conditions (13–
17), returns ADC values to normal (18). These ﬁndings are
similar to those in experimental models of stroke (18–20).
Furthermore, epidemiological studies in children suggest
that the extent of dehydration and hypocapnia at presen-
tation of DKA are the most important risk factors for CE,
again suggesting that cerebral hypoperfusion before DKA
treatment may play a role (5). Although there is indirect
evidence that cerebral hypoperfusion is involved in DKA-
related CE, reduced cerebral blood ﬂow (CBF) during
untreated DKA has not been demonstrated. We undertook
the current studies to test the hypothesis that DKA is
associated with a reduction in CBF. We also investigated
the role of hypocapnia in modulating CBF during DKA and
determined the effects of treatment with saline and insulin,
as well as treatment with bumetanide, on CBF and ADCs.
RESEARCH DESIGN AND METHODS
Induction of DKA. Four-week-old Sprague Dawley rats (150 g; Charles River
Laboratories, Wilmington, MA) were given an intraperitoneal injection of
streptozotocin (STZ) (150 mg/kg) or STZ vehicle, as described previously (18).
Rats were given unlimited access to D10W (water with 10% dextrose; Fisher
Scientiﬁc, Santa Clara, CA) in the ﬁrst 24-h period after STZ injection to
prevent hypoglycemia and were subsequently allowed unlimited access to tap
water and standard rat diet. Rats were weighed daily and urine glucose and
ketoacids (assessed as acetoacetate) determined using Multistix urinalysis
strips (Bayer; Fisher Scientiﬁc, Santa Clara, CA) as described previously (18).
Rats included in the DKA group were identiﬁed as those having urine glucose
and acetoacetate concentrations 2,000 and 160 mg/dl, respectively. To
induce dehydration and ensure acidosis, rats were deprived of drinking water
24 h before imaging. This study was conducted in accordance with the animal
use and care guidelines issued by the National Institutes of Health using a
From the
1Department of Physiology and Membrane Biology, University of
California, Davis, California; and the
2Department of Pediatrics, University
of California, Davis, California.
Corresponding author: Dr. Martha E. O’Donnell, meodonnell@ucdavis.edu.
Received 3 October 2007 and accepted 3 July 2008.
Published ahead of print at http://diabetes.diabetesjournals.org on 15 July
2008. DOI: 10.2337/db07-1410.
© 2008 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
2588 DIABETES, VOL. 57, OCTOBER 2008protocol approved by the animal use and care committee at University of
California Davis.
MR imaging analysis of CE and CBF. Both DKA and control rats were
anesthetized using sodium pentobarbital (65 mg/kg i.p.), and the left femoral
vein and artery were subsequently cannulated with PE-50 polyethylene tubing
as described previously (18). The femoral vein cannula was used for additional
anesthesia, as needed, and for administering compounds to be tested. The
femoral artery cannula was used for blood sampling. Body temperature was
monitored via rectal probe (Cole-Parmer Instruments, Vernon Hills, IL), and a
heating pad with circulating water (Gaymar, Orchard Park, NY) was used to
maintain body temperature at 36.8–37.0°C throughout surgery and brain
imaging. Rats were also subjected to tracheal intubation and ventilated
(Harvard Small Animal Ventilator; Harvard Apparatus, Holliston, MA)
throughout surgery and imaging. Ventilation was done to offset the tendency
toward respiratory depression in the anesthetized rats and thereby ensure that
the animal model closely mimicked DKA in humans. Blood samples were
taken for analysis of pCO2 and pH immediately after intubation, and the
respiratory rate and tidal volume were adjusted to maintain the pCO2 level
within the range expected for a normal physiological response to the degree
of acidosis (21). Using this method, we were able to adjust pCO2 levels such
that they were signiﬁcantly correlated with pH (correlation coefﬁcient 0.35,
P  0.04; n  33). MR diffusion–weighted spin echo images (DWIs) were
acquired using a 7-Tesla Bruker Biospec MRS/MRI system as described
previously (18,19,22). ADC values (10
6 cm
2/s) were determined from 6 
4–pixel regions of interest (ROIs) for eight brain regions (six cortex and two
striatum) using Paravision 3.0.2 software, with four gradient strengths of 5–95
mT/m (23). In each rat, CBF (ml  100 gm
1  s
1) was also determined, using
perfusion-weighted imaging analysis with continuous arterial spin labeling
(24) and a standard Bruker PERFPACK2 protocol (Bruker, Billerica, MA).
Arterial spin-labeling data were acquired using the same ﬁeld of view and slice
thickness as for DWIs, and the arterial spin-labeling ROIs were chosen from
the 128  32 matrix so as to measure CBF and ADCs on the same voxels
(18,19). Images from perfusion-weighted imaging were acquired in 11 min
using TE/TR 12.77/1,291 ms with a 1-s Adiabatic-Fast-Passage labeling pulse in
the presence of a 10 mT/m gradient to obtain inversion 8,515 Hz (2 cm)
from the isocenter (also slice center) for control and labeled images,
respectively. T1 maps for the same voxels were also acquired from selected
rats in each treatment group in order to correct CBF measurements for
possible location- and treatment-dependent variations in T1.
Experimental treatments: saline/insulin infusion. For treatment with
saline and insulin, rats were infused via cannulated femoral vein with regular
Humulin insulin at 1.5 units  kg
1  h
1 (Lilly and Company, Indianapolis, IN)
and 0.9% NaCl at 80 ml  kg
1  h
1 for 1 h followed by infusion with insulin and
saline at 1.5 units  kg
1  h
1 and 40 ml  kg
1  h
1, respectively, for the
remainder of the imaging experiment. These rates were calculated based on
comparisons of human versus rat metabolic rate, body surface area, and
percentage dehydration during DKA and were determined in initial studies to
result in biochemical changes during DKA treatment (decline in serum
glucose and urea nitrogen and resolution of acidosis) at rates similar to those
observed in children with DKA.
Bumetanide treatments. For experiments designed to determine the effects
of bumetanide on ADCs, bumetanide (30 mg/kg) was administered in one of
two ways. For rats not receiving intravenous infusion of saline/insulin,
bumetanide was injected into femoral vein cannula (0.8 ml total volume)
immediately before the start of imaging, as described previously (18). For rats
treated with saline/insulin infusion, bumetanide was given via femoral vein
cannula at the start of the saline/insulin infusion. Bumetanide (ICN Biomedi-
cals, Costa Mesa, CA) was prepared as we described (18).
Blood chemistry. Blood samples were withdrawn from the femoral artery
and abdominal artery before and after imaging, respectively, at the conclusion
of the experiment. Samples were analyzed for electrolytes, pH, blood urea
nitrogen (BUN), and glucose using an I-STAT Portable Clinical Analyzer
(I-STAT; Sensor Devices, Waukesha, WI). Blood ketoacids were assessed by
measuring -hydroxybutyrate in the blood sample using MediSense Precision
Xtra blood -ketone test strips (Abbott Laboratories, Bedford, MA).
Statistical analysis. All values are presented as means  SE. Biochemical
values were compared using Student’s t test. Within-animal changes in each of
the cortical and striatal ADCs and CBF outcomes were assessed using paired
t tests. For each of these four outcomes, a separate mixed-effects ANOVA
model of the repeated measures from each animal was used to compare
within-animal ADC and CBF changes between treatment groups. Raw (un-
transformed) values of ADCs and CBF were used in the statistical testing
procedures for these outcomes. Bivariate correlations between MR ﬁndings
(ADCs and CBF) and biochemical values were evaluated by calculating
Pearson correlation coefﬁcients. Associations between MR ﬁndings and
biochemical values were also assessed in multivariable models using multiple
linear regression. We used SAS version 9.1 for paired t tests and repeated-
measures ANOVA (Stata version 8.0; Stata, College Station, TX) for correlation
and regression analyses and Statview 5.01 for Student’s t tests. P values 0.05
were considered to indicate signiﬁcant differences, and P values between 0.05
and 0.10 were considered to represent a trend. We used 33 DKA rats for
correlation and regression analyses of baseline measures. Of these, 22 rats
were also evaluated for effects of treatments.
RESULTS
Using the methods described previously, we were able to
reliably induce DKA in the rats, with levels of acidosis and
hyperglycemia similar to those observed in children with
DKA (Table 1). Treatment for 2 h with saline/insulin
infusion resulted in improvements in acidosis and hyper-
glycemia at rates similar to those observed in human DKA.
-Hydroxybutyrate values shown were obtained using test
strips (MediSense Precision), which allowed us to use a
small volume of blood. In two experiments, we analyzed
control and DKA rat blood using a Randox Veterinary
Analyzer (Randox Laboratories, Antrim, U.K.). We found
no difference between control rat values obtained with
these two methods but twofold higher values for DKA rats
with the veterinary analyzer (not shown), suggesting that
the human test strip method used in the present study
underestimates the DKA -hydroxybutyrate values. Thus,
while further tests are needed to determine the full extent
of reduction in -hydroxybutyrate values following saline/
insulin infusion of DKA rats, our present ﬁndings suggest
that a relative decrease in -hydroxybutyrate occurs with
saline/insulin infusion.
Figure 1 shows that DKA rats had signiﬁcantly reduced
CBF, as measured by perfusion-weighted imaging. Specif-
ically, CBF was reduced by 48% in both cortex and
striatum in the DKA rats compared with control non-DKA
rats. For each rat, we evaluated ADC values in addition to
CBF and found that, consistent with our previously re-
ported observation of reduced ADCs in nonventilated DKA
rats (18), the ventilated DKA rats had signiﬁcantly reduced
ADC values, in both the cortex and striatum, compared
with control rats. The values observed were comparable
with those we reported previously. Thus, ADC values were
7.00  0.10 and 5.94  0.10 for control cortex and striatum,
respectively (n  12), and 6.43  0.13 and 4.99  0.16 for
DKA cortex and striatum, respectively (n  6). DKA ADC
values were found to be signiﬁcantly different from control
ADC values in both cortex and striatum (P  0.005 and
TABLE 1
Blood chemistry parameters
Control
DKA
preinfusion
DKA
saline/insulin
infusion
Glucose (mmol/l) 8.9  0.5 36.6  1.2* 24.8  2.5†
Sodium (mmol/l) 136.7  0.7 141.0  1.8* 156.5  2.0†
BUN (mmol/l) 6.0  0.3 35.0  3.9* 29.9  4.5
Total CO2 mmol/l 28.92  0.69 9.55  1.52* 12.45  1.84†
pH 7.44  0.02 7.07  0.04* 7.12  0.05
-Hydroxybutyrate
(mmol/l) 0.25  0.05 4.16  0.24* 2.78  0.52†
Data are means  SE for 12 control and 11 DKA rats. Plasma values
of the parameters shown were determined for control (non-DKA)
rats and DKA rats before and after2ho fsaline/insulin infusion.
*Signiﬁcantly different from control (P  0.05). †Signiﬁcantly differ-
ent from DKA preinfusion (P  0.05). Plasma values of these
parameters when evaluated following2ho fsaline/insulin/bumet-
anide infusion did not differ signiﬁcantly from those here for
saline/insulin infusion alone.
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tests). Overall, the ﬁndings presented in Fig. 1 indicate that
reduction of CBF occurs in our rat model of DKA.
In the DKA rats, cortex ADC values were signiﬁcantly
correlated with BUN concentrations (correlation coefﬁ-
cient 0.65; P  0.001) and with pH (correlation coefﬁ-
cient 0.39; P  0.02) at the time of imaging. ADC values
were not signiﬁcantly correlated with serum glucose or
sodium concentrations or with pCO2. When the biochem-
ical values were included in a multivariable linear regres-
sion model, only BUN maintained a signiﬁcant association
with ADCs (correlation coefﬁcient 0.017 [95% CI 0.026
to 0.007]; P  0.001), with higher BUN concentrations
being associated with lower ADC values. In bivariate
analyses, CBF was not signiﬁcantly correlated with any of
the biochemical measures. In a multivariable linear regres-
sion model, however, there was signiﬁcant association of
higher BUN with lower CBF (0.004 [0.007 to 0.0003];
P  0.04).
We also evaluated the effect of bumetanide on ADCs and
CBF in both control and DKA rats (Fig. 2). Bumetanide
(intravenous injection) signiﬁcantly increased ADC values
in the DKA rats to 7.17  0.20 and 5.8  0.46 for cortex and
striatum, respectively (n  6) (Fig. 2A). These values are
not signiﬁcantly different from the ADC values observed
for control non-DKA rats of 6.84  0.11 and 5.72  0.06 for
cortex and striatum, respectively, without bumetanide
(n  6) and 6.82  0.11 and 5.71  0.11 for cortex and
striatum, respectively, with bumetanide (n  6) (control
values not represented in Fig. 2A). Although bumetanide
increased ADCs in DKA rats, it had no signiﬁcant effect on
CBF of cortex or striatum in DKA rats (Fig. 2B)o ri n
control rats (1.48  0.13 vs. 1.53  0.13 ml  100 g
1  s
1
for cortex pre- and postbumetanide treatment, respec-
tively, and 1.43  0.10 vs. 1.51  0.08 ml  100 g
1  s
1 for
striatum pre- and postbumetanide treatment, respectively;
n  6 for all, data not represented in Fig. 2B). For all data
shown in Fig. 2A and B, we also evaluated mean absolute
increases as well as mean percent increases in both ADC
and CBF values relative to baseline values within each
experiment (i.e., each animal). These alternate analysis
methods produced the same results with respect to pres-
ence or absence of signiﬁcant changes in ADCs and CBF,
as shown in Fig. 2A and B (data not shown).
Hypocapnia induces vasoconstriction in cerebral blood
vessels, but it is unclear whether this effect occurs via
local direct action of pCO2 or is mediated by changes in
brain pH (25). It has been proposed previously that the
vasoconstrictive effect of hypocapnia may be absent dur-
ing acidosis (26). Thus, in the present study we tested the
effects of hypocapnia on CBF in DKA rats. pCO2 was
varied by altering the ventilation rate and tidal volume of
the anesthetized rats. Multiple measurements of CBF
made on each of ﬁve rats at varying pCO2 levels revealed
that CBF varied directly with pCO2 in DKA rats (Fig. 3). As
predicted by the Henderson-Hasselbalch equation, we also
found in these studies that plasma [H
] increased with
pCO2 in the DKA rats (not shown).
We next evaluated ADC and CBF values in DKA rats
before saline/insulin infusion and also 1 and 2 h after the
start of infusion. Figure 4 shows that saline/insulin infu-
sion caused a modest increase in ADC values of the cortex
and striatum after 2 h (3.3 and 8.0%, respectively) while
having no signiﬁcant effect after 1 h. In contrast, saline/
insulin infusion signiﬁcantly increased CBF in the cortex
of DKA rats (27 and 42% after 1 and 2 h, respectively) as
well as in the striatum (19 and 28% in the striatum after 1
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FIG. 1. Reduction of CBF in DKA rats. CBF values of cortex and
striatum in control and DKA rats were determined by perfusion-
weighted imaging. Values are means  SE; n  12 for control and n 
38 for DKA rats. *Signiﬁcantly different from control rat CBF values.
P < 0.0001 for both cortex and striatum. u, control; f, DKA.
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FIG. 2. Administering intravenous bumetanide to DKA rats normalizes ADC values without signiﬁcantly altering CBF. Rats were administered
bumetanide (30 mg/kg) immediately before the start of imaging as described in RESEARCH DESIGN AND METHODS. A: ADC values of DKA rat cortex and
striatum were determined by diffusion-weighted imaging before and 37 min after intravenous administration of bumetanide (u, Bumet; f,
Bumet). All values are means  SE, n  6. *Signiﬁcantly different from pretreatment ADC values (Bumet). P < 0.05 for both cortex and
striatum. B: CBF values of DKA rat cortex and striatum were determined by perfusion-weighted imaging before and 44 min after intravenous
administration of bumetanide. All values are means  SE, n  6. u, Bumet; f, Bumet.
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absolute increases and mean percent increases in ADC
and CBF values relative to baseline values for each animal
revealed the same results as shown in Fig. 4 with respect
to presence or absence of signiﬁcant changes (not shown).
Figures 5 shows the results of experiments conducted to
evaluate the effects of administering saline/insulin infusion
in combination with intravenous bumetanide injection. We
found that combined administration of bumetanide and
saline/insulin infusion caused signiﬁcant increases in ADC
(Fig. 5A) and CBF values (Fig. 5B) of the DKA rats after 1
and 2 h, in both cortex and striatum. When we evaluated
these data for mean absolute increases and mean percent
increases in ADCs and CBF relative to baseline for each
animal, we found the same results as shown in Fig. 5 with
respect to presence or absence of signiﬁcant changes (not
shown).
Mixed-effects ANOVA models comparing changes in
cortical and striatal ADC and CBF values before and 1 and
2 h after the start of saline/insulin infusion alone (Figs. 4A
and B) versus saline/insulin infusion with bumetanide
(Figs. 5A and B) revealed that the latter treatment resulted
in a signiﬁcantly greater elevation of striatal CBF after 1 h
(between-group contrast of mean 1-h gain for saline/
insulin with bumetanide versus saline/insulin alone  0.25
[95% CI 0.03–0.46]; P  0.027) and after 2 h (contrast of
mean 2-h gains  0.27 [0.06–0.48]; P  0.014). Between-
group comparisons trended toward statistical signiﬁcance
for 1-h gains in cortical CBF (between-group contrast 
0.17 [0.03 to 0.36]; P  0.089) and for 2-h gains in cortical
ADCs (contrast  0.28 [0.003 to 0.56]; P  0.053).
DISCUSSION
The mechanism responsible for DKA-related CE continues
to be a subject of much debate. An early case report
postulated that hypoxia/ischemia might be involved (27).
Subsequent hypotheses, however, focused mainly on the
role of osmotic ﬂuctuations during DKA treatment (28–
31). More recently, evidence has been accumulating to
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FIG. 3. Effect of pCO2 on CBF in DKA rats. DKA rats (n  5) were ventilated with varying respiratory rates and tidal volumes to vary the pCO2
level. CBF was then measured in the cortex and striatum at these varying pCO2 levels using perfusion-weighted imaging as described in RESEARCH
DESIGN AND METHODS. Data for each individual rat are plotted with a linear ﬁt for ease of identiﬁcation.
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FIG. 4. Effect of saline/insulin infusion on ADC values and CBF in DKA rats. Rats were infused with saline and insulin intravenously via
cannulated femoral vein, as described in RESEARCH DESIGN AND METHODS. A: ADC values of DKA rat cortex and striatum were determined by
diffusion-weighted imaging before, as well as 1 and 2 h after, the start saline/insulin fusion. Values are means  SE, n  6. *Signiﬁcantly different
from preinfusion ADC values by paired t test. P < 0.05 for both cortex and striatum at 2 h. One-hour values are not signiﬁcantly different from
pretreatment values. B: CBF values of DKA rat cortex and striatum were determined by perfusion-weighted imaging before, as well as 1 and 2 h
after, the start of saline/insulin infusion. Values are means  SE, n  6. *Signiﬁcantly different from preinfusion CBF values by paired t test. P <
0.01 and P < 0.001 for cortex at 1 and 2 h, respectively; P < 0.05 and P < 0.01 for striatum at 1 and 2 h, respectively. , before saline/insulin;
u, 1 hr after saline/insulin; f, 2 hr after sasline/insulin.
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The current study is the ﬁrst to provide evidence that CBF
is substantially reduced in rats with untreated DKA. Fur-
thermore, the current data demonstrate that CBF in rats
with DKA is responsive to pCO2, suggesting that local
pCO2 is an important factor controlling cerebral vascular
diameter in DKA, consistent with the hypothesis that
hypocapnia contributes to cerebral hypoperfusion and
cerebral injury in DKA. This study also conﬁrms our
previous ﬁnding of low ADC values in untreated DKA and
demonstrates that both ADCs and CBF are negatively
correlated with BUN concentrations. These data suggest
that dehydration may contribute to cerebral hypoperfu-
sion during DKA, as has been suggested in humans (5). In
sum, the current data are consistent with the hypothesis
that cerebral hypoperfusion during untreated DKA may be
a factor in the pathogenesis of CE and that DKA-related
CE is mechanistically similar to CE resulting from other
types of ischemic brain injury.
The present study also demonstrates that treating rats
with intravenous bumetanide increases ADCs without
signiﬁcant effects on CBF. In contrast, in DKA rats treated
with a saline/insulin infusion protocol similar to that used
clinically, CBF values return toward normal levels, while a
more gradual increase in ADCs is observed. When bumet-
anide was added to saline/insulin infusion, greater in-
creases in CBF were observed in the striatum and there
was a trend toward greater ADC increase in the cortex.
The implications of these ﬁndings are not yet clear and
bear further study. More rapid increases in ADCs may
indicate more rapid resolution of cytotoxic CE with bu-
metanide treatment, but whether this improves the cere-
bral metabolic state and decreases the likelihood of
cerebral injury has not been established. Vasogenic edema
has been found to occur after several hours of DKA
treatment in children. Whether the initial cytotoxic edema
occurring during untreated DKA or the later development
of vasogenic edema during prolonged DKA treatment is
more important in causing cerebral injury is unknown.
Furthermore, the effects of bumetanide on the develop-
ment of vasogenic edema later in the course of DKA
treatment have not been investigated. Additional investi-
gations of more prolonged DKA treatment, and the effects
of bumetanide on cerebral metabolic alterations, will help
to resolve these questions.
The present study provides additional information about
the pathophysiology of DKA-related CE, a topic that has
puzzled clinicians for decades. Because symptoms of
increased intracranial pressure often become apparent
during DKA treatment, many investigators hypothesized
that rapid changes in serum osmolality and/or rapid ﬂuid
infusion during DKA treatment are responsible (28,32,33).
This hypothesis has been questioned, however, because
studies (5,6,10) have documented the occurrence of both
subclinical CE and overt, symptomatic CE before DKA
treatment. Recent studies (3,5,6) have also demonstrated
that dehydration and hypocapnia during DKA, rather than
changes in osmolality, are the factors most strongly cor-
related with risk for CE. These associations imply that
cerebral hypoperfusion during DKA, before DKA treat-
ment, may play a role in causing cerebral injury and edema
formation. A reduction in baseline CBF, before onset of
DKA, may also contribute, as reduced CBF in children
with type 1 diabetes without DKA has been demonstrated
(34). The current study further reinforces these associa-
tions because elevated BUN concentrations (indicating
greater dehydration) correlated with lower CBF and ADC
values in our rat model, suggesting greater CE in associa-
tion with lower circulatory volume.
Beyond epidemiological studies of risk factors, addi-
tional support for an association between cerebral hypo-
perfusion and DKA-related CE is suggested by the fact that
DKA-related CE shares several characteristics with edema
caused by cerebral hypoxia/ischemia. Our previous stud-
ies, as well as our present ﬁndings, demonstrate that ADC
values are decreased in rats with untreated DKA, similar to
decreased ADCs observed in both animal models and
humans with stroke or other ischemic brain injuries (18).
Similarly, in a previous study (18), as well as in the present
study, we found that bumetanide treatment of rats with
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FIG. 5. Effect of saline/insulin/bumetanide infusion on ADC values and CBF in DKA rats. Rats were administered bumetanide (30 mg/kg) at the
start of saline/insulin infusion as described in RESEARCH DESIGN AND METHODS. A: ADC values of DKA rat cortex and striatum were determined by
diffusion-weighted imaging before, as well as 1 and 2 h after, the start of insulin/saline infusion containing bumetanide. Values are means  SE,
n  11. For one rat, valid imaging data were not collected 1 h postinfusion due to technical problems. *Signiﬁcantly different from preinfusion
ADC values by paired t test. P < 0.01 and P < 0.0001 for cortex at 1 and 2 h, respectively; P < 0.01 and P < 0.001 for striatum at 1 and 2 h,
respectively. B: CBF values of DKA rat cortex and striatum were determined by diffusion-weighted imaging before, as well as 1 and 2 h after, the
start of insulin/saline infusion containing bumetanide. Values are means  SE, n  11. *Signiﬁcantly different from preinfusion CBF values by
paired t test. P < 0.001 and P < 0.01 for cortex at 1 and 2 h, respectively; P < 0.001 for striatum at 1 and at 2 h. , before saline/insulin/bumet;
u, 1 h after saline/insulin/bumet; f, 2 h after saline/insulin/bumet.
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edema. Finally, MR imaging studies of children with DKA
suggest that after several hours of DKA treatment with
intravenous ﬂuids and insulin, ADC values are elevated
above those of normal control subjects and cerebral
perfusion is increased, consistent with vasogenic edema
(35). These ﬁndings likewise parallel those of hypoxic/
ischemic cerebral injury, in which a period of hyperemia
and vasogenic edema generally develops after reperfusion
of ischemic cerebral tissue (36–38). Our ﬁndings demon-
strate that CBF remains responsive to pCO2 during DKA,
suggesting that the rise in pCO2 during DKA treatment,
independent of ﬂuid resuscitation, might result in reperfu-
sion with hyperemia. Most importantly, the current study
demonstrates that CBF is indeed substantially decreased
in rats with untreated DKA, consistent with our hypothesis
that DKA-related CE is caused by cerebral hypoperfusion.
Although the reduced CBF values in most DKA rats were
not in the range known to cause ischemic injury, it is likely
that CBF reduction may reach these extremes only in the
most severely ill animals. This situation parallels that of
human DKA, in which only a small minority of children
(1%) has cerebral injury resulting from DKA, although
many, if not most, have some evidence of asymptomatic
CE. It is likely that this reduction in CBF is the result of
multiple factors, including reduced circulatory volume due
to dehydration and cerebral vasoconstriction caused by
hypocapnia.
The present study provides preliminary information,
suggesting potential therapies to reduce CE and cerebral
injury during DKA. Studies of ischemia and ischemia/
reperfusion in rat models of stroke have shown that
bumetanide reduces both CE and infarct (19,39). In those
studies, it was found that the blood-brain barrier (BBB)
Na-K-Cl cotransporter is present in the luminal BBB
membrane (19) and is stimulated by ischemic conditions
(19,40,41). It was also found that in the early hours of
permanent middle cerebral artery occlusion, before break-
down of the BBB occurs (42–44), intravenous adminis-
tration of bumetanide to inhibit the BBB Na-K-Cl
cotransporter reduces CE, as assessed by DWI determina-
tion of ADCs as well as by gravimetric evaluation of brain
water (19). Bumetanide also reduces the middle cerebral
artery occlusion–induced brain infarct, as assessed by
2,3,5-triphenyltetrazolium chloride staining of brain slices
(19). In other studies (39,45) using reversible middle
cerebral artery occlusion to produce ischemia/reperfusion
in rats, bumetanide administered via dialysis to the corti-
cal parenchyma was similarly found to reduce brain water
and infarct, as determined by gravimetry and 2,3,5-triphe-
nyltetrazolium chloride staining. Evidence has been pro-
vided that the BBB cotransporter participates in ischemia-
induced hypersecretion of sodium, chloride, and water
from blood into brain during stroke (19,40,41) such that
inhibiting the BBB cotransporter attenuates CE. However,
the Na-K-Cl cotransporter can also cause hypoxia-induced
cell swelling of both BBB endothelial cells (40) and
astrocytes (41,46). The present ﬁnding that bumetanide
increases cerebral ADC values in the DKA rats is consis-
tent with the hypothesis that in DKA, cell swelling is
diminished by inhibition of Na-K-Cl cotransport. Further
study is needed to more fully evaluate the therapeutic
potential of bumetanide and to determine whether, in fact,
bumetanide attenuates CE by reducing swelling of the
BBB and astrocytes in DKA.
The current study has some limitations. As previously
noted, rats with DKA tended to have respiratory depres-
sion with administration of anesthesia. For this reason,
rats were intubated and mechanically ventilated, and we
adjusted ventilator settings to approximate physiological
hyperventilation in response to acidosis. Because of the
inherent limitations of the ventilator equipment, however,
it was difﬁcult to precisely adjust pCO2 levels to correlate
with pH levels within narrow ranges. Therefore, pCO2
levels in some rats may have been somewhat higher or
lower than expected physiologically, and we were limited
in our ability to evaluate correlations between hypocapnia
and changes in ADCs or CBF. Furthermore, CBF values,
even in normal control rats, varied considerably among
individual rats. This baseline variation limited our ability
to detect associations between biochemical variables and
differences in CBF in DKA rats. For example, although we
observed a clear association between pCO2 and CBF when
individual rats were evaluated over several different pCO2
values, no association between pCO2 and CBF could be
detected when only single measurements were made for
each individual rat. In addition, barbiturate anesthesia
typically causes a decline in CBF and likely had some
effect in the current studies. In general, however, DKA rats
required a lower dosage of anesthetic compared with that
required by control rats. Therefore, it would be unlikely
that anesthetic effect alone could explain the decrease in
CBF in DKA rats. In addition, in our rat DKA model, the
severity of DKA varied among rats, similar to human DKA.
Because of variations in DKA severity, however, mean
initial CBF and ADC values for the different conditions
studied also differed among experiments. Finally, in these
studies, induction of DKA in rats resulted in the develop-
ment of mild, subclinical CE, modeling that which devel-
ops in most children with DKA. By studying this condition,
we aimed to gain insights into the causes of more severe,
clinically manifest CE that occurs in a small minority of
children and may represent the most extreme end of a
continuum of manifestations. It is possible, however, that
clinically manifest CE in these children results from addi-
tional factors not studied in these experiments. Nonethe-
less, determining the cerebral alterations commonly
associated with DKA provides initial information impor-
tant to the eventual understanding of DKA-related CE and
cerebral injury.
In summary, untreated DKA in rats is associated with
reduced CBF, as well as with low ADC values indicating
CE. Both ADC and CBF values were lowest in the animals
with the greatest dehydration, and CBF values in individ-
ual rats varied in response to changes in pCO2. These
ﬁndings strengthen the hypothesis that dehydration and
hypocapnia during DKA result in diminished CBF and that
cerebral hypoperfusion may be important in the pathogen-
esis of DKA-related CE. The present study also provides
further evidence for the hypothesis that Na-K-Cl cotrans-
port participates in CE formation during DKA and suggests
that treatment with bumetanide to reduce edema forma-
tion should be further investigated.
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